Note: EPS may not be comparable

Senseonics Holdings (NYSE: SENS) reported Q4 EPS of ($0.12), $0.01 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $2.97 million versus the consensus estimate of $2.97 million.

RECENT HIGHLIGHTS & ACCOMPLISHMENTS:

• FDA clinical chemistry and toxicology device panel scheduled for March 29, 2018 to review the Eversense system
• Launched Eversense XL, the world’s longest CGM sensor life with up to 180 days continuous use, in the United Kingdom in fourth quarter 2017 and most recently into Sweden
• Revenue of $2.9 million in the fourth quarter 2017 and $6.4 million in the full year 2017
• Completed convertible notes offering which resulted in $51.3 million in aggregate net proceeds

2018 FINANCIAL OUTLOOK

Management projects revenue for full year 2018 to be in the range of $18.0 to $20.0 million.

GUIDANCE:

Senseonics Holdings sees FY2018 revenue of $18-20 million, versus the consensus of $28.18 million.

For earnings history and earnings-related data on Senseonics Holdings (SENS) click here.